Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dravet Syndrome Indication Will Set GW Pharma Apart On US Epilepsy Market

Executive Summary

GW Pharma is on track for 2017 filings for its marijuana-derived epilepsy therapy, Epidiolex (cannabidiol), following more positive data from the third Phase III study for the drug to be presented this year – however, Epidiolex's potential in Dravet syndrome will be its competitive edge to set GW apart from rivals.

Advertisement

Related Content

Glioma A New Therapeutic Area Of Interest For GW Pharma
Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel